• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»AptarGroup

AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray

By Pallavi Madhiraju on March 21, 2026   Medical Devices & Diagnostics  

AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray

Aptar’s UDS Powder system enters ENA Respiratory’s POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.

Aptar Pharma and COVIRIX Medical partner to develop inhaled broad-spectrum antiviral treatment

By Pallavi Madhiraju on March 13, 2026   Pharma & Biotech  

Aptar Pharma and COVIRIX Medical partner to develop inhaled broad-spectrum antiviral treatment

Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes